The effects of COVID-19 on New York State’s Drug User Health Hubs and syringe service programs: a qualitative study

[1]  T. Gift,et al.  Impact of the COVID-19 Pandemic on Chlamydia and Gonorrhea Tests Performed by a Large National Laboratory—United States, 2019 to 2020 , 2022, Sexually transmitted diseases.

[2]  D. D. Des Jarlais,et al.  Harm reduction and health services provided by syringe services programs in 2019 and subsequent impact of COVID-19 on services in 2020 , 2022, Drug and Alcohol Dependence.

[3]  Alex S. Bennett,et al.  The COVID-19 pandemic and the health of people who use illicit opioids in New York City, the first 12 months , 2021, International Journal of Drug Policy.

[4]  P. Mateu-Gelabert,et al.  The impact of COVID-19 on people who inject drugs in New York City: increased risk and decreased access to services , 2021, Harm Reduction Journal.

[5]  Elizabeth A Torrone,et al.  Trends in Nationally Notifiable Sexually Transmitted Disease Case Reports During the US COVID-19 Pandemic, January to December 2020 , 2021, Sexually transmitted diseases.

[6]  E. Williams,et al.  Program Adaptations to Provide Harm Reduction Services During the COVID-19 Pandemic: A Qualitative Study of Syringe Services Programs in the U.S. , 2021, AIDS and Behavior.

[7]  G. Chi,et al.  Impact of the COVID-19 Pandemic on Chlamydia and Gonorrhea Screening in the U.S. , 2021, American Journal of Preventive Medicine.

[8]  J. Buxton,et al.  Pathways between COVID-19 public health responses and increasing overdose risks: A rapid review and conceptual framework , 2021, International Journal of Drug Policy.

[9]  B. Lambdin,et al.  Ingenuity and resiliency of syringe service programs on the front lines of the opioid overdose and COVID-19 crises , 2021, Translational Research.

[10]  J. Weiss,et al.  Telemedicine increases access to buprenorphine initiation during the COVID-19 pandemic , 2021, Journal of Substance Abuse Treatment.

[11]  Pui Ying Chan,et al.  COVID-19 Outbreak — New York City, February 29–June 1, 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[12]  S. Solanki,et al.  Telemedicine, the current COVID-19 pandemic and the future: a narrative review and perspectives moving forward in the USA , 2020, Family Medicine and Community Health Journal.

[13]  D. Ompad,et al.  “They look at us like junkies”: influences of drug use stigma on the healthcare engagement of people who inject drugs in New York City , 2020, Harm Reduction Journal.

[14]  S. Friedman,et al.  Challenges posed by COVID‐19 to people who inject drugs and lessons from other outbreaks , 2020, Journal of the International AIDS Society.

[15]  P. Haber,et al.  Challenges in maintaining treatment services for people who use drugs during the COVID-19 pandemic , 2020, Harm Reduction Journal.

[16]  D. D. Des Jarlais,et al.  The Impact of COVID-19 on Syringe Services Programs in the United States , 2020, AIDS and Behavior.

[17]  N. Dey.  COVID-19 Outbreak , 2020, Data Analytics for Pandemics.

[18]  M. Golden,et al.  The impact of localized implementation: determining the cost-effectiveness of HIV prevention and care interventions across six United States cities. , 2019, AIDS.

[19]  Dylan H Roby,et al.  Telemedicine-delivered treatment interventions for substance use disorders: A systematic review. , 2019, Journal of substance abuse treatment.

[20]  J. Hollander,et al.  On‐demand synchronous audio video telemedicine visits are cost effective , 2019, The American journal of emergency medicine.

[21]  R. Pollini,et al.  Stigma at every turn: Health services experiences among people who inject drugs. , 2018, The International journal on drug policy.

[22]  Roxanne Nelson.  Telemedicine and Telehealth: The Potential to Improve Rural Access to Care. , 2017, The American journal of nursing.

[23]  G. Duarte,et al.  Effectiveness of needle and syringe Programmes in people who inject drugs – An overview of systematic reviews , 2017, BMC Public Health.

[24]  M. Hellard,et al.  Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: a systematic review and meta-analysis. , 2014, International journal of epidemiology.

[25]  A. Abdul-Quader,et al.  Effectiveness of Structural-Level Needle/Syringe Programs to Reduce HCV and HIV Infection Among People Who Inject Drugs: A Systematic Review , 2013, AIDS and Behavior.

[26]  P. Vickerman,et al.  Combination Interventions to Prevent HCV Transmission Among People Who Inject Drugs: Modeling the Impact of Antiviral Treatment, Needle and Syringe Programs, and Opiate Substitution Therapy , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  J. Parry,et al.  The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. , 2011, Addiction.

[28]  D. D. Des Jarlais,et al.  Systematic Review and Meta-Analysis of Interventions to Prevent Hepatitis C Virus Infection in People Who Inject Drugs , 2011 .

[29]  D. D. Des Jarlais,et al.  Doing harm reduction better: syringe exchange in the United States. , 2009, Addiction.

[30]  P. Sainsbury,et al.  Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. , 2007, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[31]  Hsiu-Fang Hsieh,et al.  Three Approaches to Qualitative Content Analysis , 2005, Qualitative health research.

[32]  Helen C Noel,et al.  Home telehealth reduces healthcare costs. , 2004, Telemedicine journal and e-health : the official journal of the American Telemedicine Association.

[33]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[34]  Z. Agha,et al.  Cost effectiveness of telemedicine for the delivery of outpatient pulmonary care to a rural population. , 2002, Telemedicine journal and e-health : the official journal of the American Telemedicine Association.

[35]  D. Vlahov,et al.  The role of needle exchange programs in HIV prevention. , 1998, Public health reports.

[36]  M. Alter,et al.  Reduced risk of hepatitis B and hepatitis C among injection drug users in the Tacoma syringe exchange program. , 1995, American journal of public health.